News: Genera Biosystems distributing molecular diagnostics assays in India

Genera Biosystems (ASX:GBI) has entered into an agreement with Genecell Diagnostics Private Limited to supply its AmpaSand based molecular diagnostics assays to two selected pathology groups in the Indian market.   

India's medical diagnostics market size is currently worth about US$3.2 billion per annum of which 10% is in the organised pathology sector with substantial market fragmentation and challenges existing outside of this space.

Under the agreement, CSDA Genecell has been granted the right to distribute Genera’s AmpaSand MDx assays to its CureHealth Diagnostics pathology lab subsidiary and SRL Diagnostics.

Genera is working with Genecell to support it to undertake its internal assay validation in late August with commercial shipments of kits anticipated to take place late in Q3 CY2015 and first customer receipts expected early in Q4 of CY2015.   

CureHealth operates a specialised pathology MDx reference laboratory in New Delhi servicing the Delhi and National Capital Region (NCR) territory markets and has an exclusive marketing agreement with SRL Diagnostics for its HPV mRNA test in the cervical cancer screening domain, pan India.

SRL is the leading and reputed national lab network in India with a 43% market share of the organised Indian pathology sector.

With 258 labs (of which 12 are high-end laboratories) and 6,300 collection points, SRL has the second largest pathology network in Asia conducting more than 107,000 tests a day ranging from simple to high-end tests.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.